Immix Biopharma, Inc.

Kurta Law is investigating brokers who recommended that their clients purchase shares of Immix Biopharma, Inc. This investment came with substantial risks that made it unsuitable for many investors. These risks appear in the prospectus, the SEC filing that companies use to disclose their business strategy and related risks prior to offering the securities for sale. Unsuitable investments violate FINRA Rule 2111 and Regulation Best Interest, and investors who incur losses may be able to recover via FINRA arbitration.

If your broker recommended that you invest in Immix Biopharma, you may have a claim against the firm through FINRA arbitration.  FINRA arbitration offers a quicker and cheaper remedy for investors than suing in civil court. Contact (877) 600-0098 or email info@kurtalawfirm.com to speak to a securities attorney for free today.

What is Immix Biopharma?

Immix Biopharma is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics (“TSTx”) in oncology and inflammation, according to the company.

As of the date of the prospectus filing, the company had not generated any revenues.

Investors should also know that Immix Biopharma is registered as an emerging growth company, meaning that it can make limited disclosures in its prospectus. Less information generally means more risk.

Immix Biopharma Stock

Immix Biopharma (IMMX) investments involve a high degree of risk, according to the company’s prospectus. The company debuted at $5.00 per share and recently traded at $2.20 per share. This massive drop in value was not surprising, given the risks clearly disclosed in the company’s prospectus.

Risks Associated with Immix Biopharma Investments

Brokerage firms that approve an investment are required to understand the risks associated with an investment. Furthermore, brokers must accurately represent the risks associated with certain investments.

The prospectus states at the beginning of the “Risk Factors” section: “We have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses for the foreseeable future.

As of the date of the prospectus, significant additional financing was needed to fund the operation, development, and if approved, the commercialization of product candidates. The company had no source of revenue and there was substantial doubt about the company’s ability to continue as an ongoing concern. The limited number of product candidates were still in early clinical or pre-clinical development. Difficulty enrolling patients in clinical trials could cause potential delays or prevent the start of clinical trials. Before commercialization, Immix Biopharma would need to obtain necessary regulatory approvals. Results of pre-clinical studies and clinical requirements may not satisfy FDA requirements. Compliance with regulations is time-consuming and could cut into the profitability of the drug overall.  Even if product candidates receive regulatory approval, there is no guarantee that Immix Biopharma would successfully bring the drug to market or that there would be significant sales. 

ThinkEquity Underwriter

ThinkEquity served as the underwriter of Immix Biopharma. Investors should know about this broker’s potential conflicts of interest. An underwriter should keep potentially overly risky investments from trading on the public stock market. But because underwriters make money by bringing new stocks to market, they may have motivation to overlook certain risks.

What Can I Do If I Suffered Losses?

If you lose money due to investments in Immix Biopharma, consider reaching out to a Kurta Law securities attorney. Our securities attorneys have 5-star reviews on Google and a proven track record when it comes to securing fair settlements for our clients. Call (877) 600-0098 or email info@kurtalawfirm.com.